About OnDosis
OnDosis is a Healthcare company based in Goteborg (Sweden) founded in 2017. Oral drug delivery systems for individualized micro-unit dosing are developed. OnDosis has raised $14.45 million across 4 funding rounds from investors including Astrazeneca, University of Gothenburg and European Union. OnDosis offers products and services including Dosage Manager and Connected Services. Its focus areas include Life Sciences, Drug Delivery and Oral. Its legal entity is OnDosis AB.
Company details
OnDosis was founded in 2017 in Gothenburg, Sweden, within the health technology sector. Focus is placed on creating oral drug delivery systems, including the OnDosis 01 device, which enables precise, individualized dosing of oral medications in micro-unit volumes. This approach supports patients with conditions such as attention-deficithyperactivity disorder (ADHD) who face challenges in maintaining consistent medication schedules. Operations center on advancing drug administration technologies for improved patient compliance.
- Headquarters Goteborg, Sweden
- SectorsHealthcare
- Website ondosis.com
- Social LinkedIn X
- Legal Name Ondosis Ab
- Total Equity Funding$14.45M (USD)
in 4 rounds
- Latest Funding Round$11.05M (USD), Series B
May 2021
- InvestorsAstrazeneca
& 5 more
Products & Services of OnDosis
OnDosis offers a comprehensive portfolio of products and services, including Dosage Manager and Connected Services.
App for individualized medicine dosing and treatment optimization.
Suite linking patients, physicians, and data for better outcomes.
Funding Insights of OnDosis
OnDosis has successfully raised a total of $14.45M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $11.05 million completed in May 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $14.45M
- Total Rounds 4
- Last Round Series B — $11.05M
- First Round $56,027
(Apr 2019)
- Investors Count 6
All 4 funding rounds of OnDosis with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2021 | $11.05M | Series B | – | Aeternum | |
| Sep 2020 | $3.4M | Series A | – | – | |
| Sep 2019 | $54,684 | Grant | – | – | |
| Apr 2019 | $56,027 | Grant | – | – |
6 investors in total: 6 institutional.
Investors in OnDosis
OnDosis has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Astrazeneca, University of Gothenburg and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Long-term value is created through active ownership in Nordic companies. | aeternumcapital.no | Oslo, Norway | ||
VC firm focused on multiple sectors | diginvestment.com | Stockholm, Sweden | ||
Government agency and accelerator focusing on innovative startups and SMEs | eicfund.eu | Brussels, Belgium | ||
Pharmaceutical and biologics products are developed and distributed worldwide. | 1913 | astrazeneca.com | Cambridge, United Kingdom | |
Diversified courses and degrees are offered across multiple streams. | gu.se | Gothenburg, Sweden | ||
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for OnDosis
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of OnDosis
5 people are tracked at OnDosis (4 in leadership, 1 in team).
| Name | Role | Group |
|---|---|---|
Martin Olovsson | CEO and co-founder | Leadership |
Joshua Carney | Chief Digital Officer (CDO) | Leadership |
Stina Wigren | Chief Operating Officer | Leadership |
Jonas Bäck | Head of Business Development | Leadership |
Tomas Lindström | Supply Chain Manager | Team |
Complete people profiles for OnDosis
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of OnDosis
3 dated milestones of OnDosis across 4 years, from founding to its latest funding, stage changes and deals.
- Founded OnDosis is founded.
- Funding First funding round of $56K.
- Funding Latest funding round, Series B, of $11.1M.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ondosis
Complete news archive for OnDosis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about OnDosis
OnDosis was founded in 2017 and raised its 1st funding round 2 years after it was founded.
OnDosis is headquartered in Goteborg, Sweden. It is registered at Goteborg, Vastra Gotaland, Sweden.
OnDosis is a funded company, having raised a total of $14.45M across 4 funding rounds to date. The company's 1st funding round was a Grant of $56.03K, raised on Apr 2019.
OnDosis was founded in 2017 in Gothenburg, Sweden, within the health technology sector. Focus is placed on creating oral drug delivery systems, including the OnDosis 01 device, which enables precise, individualized dosing of oral medications in micro-unit volumes. This approach supports patients with conditions such as attention-deficithyperactivity disorder (ADHD) who face challenges in maintaining consistent medication schedules. Operations center on advancing drug administration technologies for improved patient compliance.
OnDosis offers Dosage Manager and Connected Services.
OnDosis has 6 investors. Key investors include Astrazeneca, University of Gothenburg, European Union, Aeternum Capital, and DIG Investment.
OnDosis operates through Ondosis Ab.